Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform
Achievement of high targeting efficiency for a drug delivery system remains a challenge of tumor diagnoses and nonsurgery therapies. Although nanoparticle-based drug delivery systems have made great progress in extending circulation time, improving durability, and controlling drug release, the targe...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2021/8502021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546216283471872 |
|---|---|
| author | Pengyu Gao Dan Zou Ansha Zhao Ping Yang |
| author_facet | Pengyu Gao Dan Zou Ansha Zhao Ping Yang |
| author_sort | Pengyu Gao |
| collection | DOAJ |
| description | Achievement of high targeting efficiency for a drug delivery system remains a challenge of tumor diagnoses and nonsurgery therapies. Although nanoparticle-based drug delivery systems have made great progress in extending circulation time, improving durability, and controlling drug release, the targeting efficiency remains low. And the development is limited to reducing side effects since overall survival rates are mostly unchanged. Therefore, great efforts have been made to explore cell-driven drug delivery systems in the tumor area. Cells, particularly those in the blood circulatory system, meet most of the demands that the nanoparticle-based delivery systems do not. These cells possess extended circulation times and innate chemomigration ability and can activate an immune response that exerts therapeutic effects. However, new challenges have emerged, such as payloads, cell function change, cargo leakage, and in situ release. Generally, employing cells from the blood circulatory system as cargo carriers has achieved great benefits and paved the way for tumor diagnosis and therapy. This review specifically covers (a) the properties of red blood cells, monocytes, macrophages, neutrophils, natural killer cells, T lymphocytes, and mesenchymal stem cells; (b) the loading strategies to balance cargo amounts and cell function balance; (c) the cascade strategies to improve cell-driven targeting delivery efficiency; and (d) the features and applications of cell membranes, artificial cells, and extracellular vesicles in cancer treatment. |
| format | Article |
| id | doaj-art-b472db4fc3da4da4a2cb103a29de893e |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-b472db4fc3da4da4a2cb103a29de893e2025-02-03T07:23:31ZengWileyStem Cells International1687-966X1687-96782021-01-01202110.1155/2021/85020218502021Design and Optimization of the Circulatory Cell-Driven Drug Delivery PlatformPengyu Gao0Dan Zou1Ansha Zhao2Ping Yang3Key Laboratory for Advanced Technologies of Materials, Ministry of Education, School of Material Science and Engineering, Southwest Jiaotong University, Chengdu 610031, ChinaKey Laboratory for Advanced Technologies of Materials, Ministry of Education, School of Material Science and Engineering, Southwest Jiaotong University, Chengdu 610031, ChinaKey Laboratory for Advanced Technologies of Materials, Ministry of Education, School of Material Science and Engineering, Southwest Jiaotong University, Chengdu 610031, ChinaKey Laboratory for Advanced Technologies of Materials, Ministry of Education, School of Material Science and Engineering, Southwest Jiaotong University, Chengdu 610031, ChinaAchievement of high targeting efficiency for a drug delivery system remains a challenge of tumor diagnoses and nonsurgery therapies. Although nanoparticle-based drug delivery systems have made great progress in extending circulation time, improving durability, and controlling drug release, the targeting efficiency remains low. And the development is limited to reducing side effects since overall survival rates are mostly unchanged. Therefore, great efforts have been made to explore cell-driven drug delivery systems in the tumor area. Cells, particularly those in the blood circulatory system, meet most of the demands that the nanoparticle-based delivery systems do not. These cells possess extended circulation times and innate chemomigration ability and can activate an immune response that exerts therapeutic effects. However, new challenges have emerged, such as payloads, cell function change, cargo leakage, and in situ release. Generally, employing cells from the blood circulatory system as cargo carriers has achieved great benefits and paved the way for tumor diagnosis and therapy. This review specifically covers (a) the properties of red blood cells, monocytes, macrophages, neutrophils, natural killer cells, T lymphocytes, and mesenchymal stem cells; (b) the loading strategies to balance cargo amounts and cell function balance; (c) the cascade strategies to improve cell-driven targeting delivery efficiency; and (d) the features and applications of cell membranes, artificial cells, and extracellular vesicles in cancer treatment.http://dx.doi.org/10.1155/2021/8502021 |
| spellingShingle | Pengyu Gao Dan Zou Ansha Zhao Ping Yang Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform Stem Cells International |
| title | Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform |
| title_full | Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform |
| title_fullStr | Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform |
| title_full_unstemmed | Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform |
| title_short | Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform |
| title_sort | design and optimization of the circulatory cell driven drug delivery platform |
| url | http://dx.doi.org/10.1155/2021/8502021 |
| work_keys_str_mv | AT pengyugao designandoptimizationofthecirculatorycelldrivendrugdeliveryplatform AT danzou designandoptimizationofthecirculatorycelldrivendrugdeliveryplatform AT anshazhao designandoptimizationofthecirculatorycelldrivendrugdeliveryplatform AT pingyang designandoptimizationofthecirculatorycelldrivendrugdeliveryplatform |